News – Page 885 – Endpoints News

Alkermes' head of early R&D jumps ship to newly created Harvard role

6 years ago

Gilead submits an NDA for its big blockbuster hopeful

6 years ago

HHMI discriminated against two Asian American women investigators, lawsuits allege

6 years ago

With eye on winning over FDA in the wake of RTF, Zogenix publishes new Fintepla data

6 years ago

Poxel passes 3rd straight Phase III diabetes trial in Japan, but what's going on with US/EU partner Roivant?

6 years ago

On the heels of pocketing $30M from Alexion, Stealth Bio says its PhIII was a flop

6 years ago

Top 10 surprises for biopharma in 2020? Cowen's biotech team offers a few ideas to chew on

6 years ago

As Congo Ebola outbreak festers, FDA approves first vaccine to combat deadly virus

6 years ago

Biogen makes cautious bet on dry AMD as partner Catalyst Bio moves anti-C3 drug toward the clinic

6 years ago

Kinnate jumps onto the biotech stage with $74.5M and a fledgling cancer drug pipeline

6 years ago

FDA drafts guidance on demonstrating substantial evidence of effectiveness

6 years ago

NIH-directed purge of researchers with China ties sweeps up Moffitt CEO Alan List, colleagues

6 years ago

Biogen hands over $45M cash to license a tau project for Alzheimer's; Novartis launches a lottery for free dose of ...

6 years ago

Novartis elects to keep one heart drug, discard the other from option deal with Akcea, Ionis

6 years ago

Forma Therapeutics bounces back from Celgene fallout with $100 million Series D

6 years ago

Jazz rolls the dice on a billion-dollar gamble on a new drug for SCLC — shooting for a 2020 launch

6 years ago

Takeda puts $120M in near-term cash on the table to complete a new oncology platform deal

6 years ago

Deerfield adds Duke to its roster of college partners, kicking off a $130M discovery alliance

6 years ago

Flagship bankrolls quest to create gene therapy 2.0, with new viral delivery tech in hand

6 years ago

Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas

6 years ago

Harvard taps Tishman Speyer to manage first phase of its new 36-acre research campus — and biotechs can't wait

6 years ago

Another depression trial goes bust, as Minerva drug fails PhII study

6 years ago

Tox issues? Check. Questionable efficacy data? Check. OK to market? ODAC says check that box for Epizyme

6 years ago

After being repeatedly jilted, this biotech was swept off its feet in a race to ASH: Inside Merck's $2.7B ArQule ...

6 years ago

First page Previous page 882 883 884885886 887 888 Next page Last page